Pharmacodynamics H-desmopressin spray is specifically targeted at the pathogenesis of diabetes insipidus, the main symptoms of which are excessive urine (polyuria) and its low density (hypoisostenuria). The reason for polyuria lies in the deficit of the antidiuretic nanopeptide neurohormone vasopressin, produced in the hypothalamus. This hormone regulates the osmolarity and osmotic pressure of liquids in the body, and also stimulates the reverse absorption (reabsorption) of water in the tubule system of renal nephrons.
The drug H-desmopressin spray contains a synthetic analogue of the endogenous hormone arginine-vasopressin, the active substance desmopressin acetate (DDAVP, 1-deamino-8-arginine vasopressin). Its structure was altered, which repeatedly increased vasopressor activity and effects on the V2-receptors of renal tubule cells.
H-desmopressin spray helps increase the permeability of the renal tubular membrane, which leads to increased water reabsorption and, consequently, to a decrease in the volume of excreted urine. In addition, the osmolar concentration of urine increases and the osmolarity of the blood plasma decreases, and this reduces the frequency of urination, including at night.